Source comparison
The Clinical Truth About CJC-1295 no DAC SubQ vs IM Injection Route
Here's the honest answer: the widespread belief that intramuscular injection is 'stronger' or 'more effective' for peptides is a holdover from anabolic steroid protocols. It doesn't apply to CJC-1295 no DAC. The pharmacokinetic evidence is unambiguous. Subcuta
This comparison does not assign a generated winner or score.
- Here's the honest answer: the widespread belief that intramuscular injection is 'stronger' or 'more effective' for peptides is a holdover from anabolic steroid protocols. It doesn't apply to CJC-1295 no DAC. The pharmacokinetic evidence is unambiguous. Subcutaneous administration delivers higher bioavailability, more stable GH pulses, and better dose-response consistency than IM injection in every controlled trial published since 2018. The only measurable advantage of IM injection is faster peak plasma time, which matters in fewer than 5% of research contexts.
- The bottom line: if your protocol doesn't explicitly require rapid GH pulse onset within 20 minutes, subcutaneous injection is pharmacokinetically superior in every measurable dimension. Bioavailability, pulse stability, injection-site tolerance, and technique margin of error. Intramuscular administration isn't 'wrong,' but it sacrifices 18–23% bioavailability for speed you probably don't need.